hiv-in-5

HIV-IN-5 (compound 5r) 是 HIV-1 的有效抑制剂 (IC50: 0.16 μM)。HIV-IN-5 能够与 NNIBP (NNRTIs (非核苷逆转录酶抑制剂) 结合位点) 相结合。HIV-IN-5 能够抑制 HIV DNA 依赖的 DNA 聚合作用 (IC50: 2.18 μM)。

UC-781 (NSC-675186) 是一种高效且具有选择性的人类免疫缺陷病毒 HIV-1 非核苷类逆转录酶(NNRTI)I抑制剂 ，C50 值为 5 nM。UC-781 具有抗病毒活性和耐药性。UC-781状态稳定，较低的 PH 或不同温度对其影响较小。

DENV-IN-5 是一种有效且具有选择性的登革热病毒 (DENV) 抑制剂，对 DENV-I ∼ IV 的 EC50 值分别为 1.47、9.23、7.08、8.91 μM， 对HIV-1IIIB 的EC50 为 0.1512 μM。

Berberine (Umbellatine) 属于生物碱类天然产物，可以激活 AMPK、抑制 DNA 拓扑异构酶、诱导 ROS 生成。Berberine 具有抗肿瘤、抗菌、降血糖、降血脂等生物学活性。

Ebselen (CCG-39161) 是一种谷胱甘肽过氧化物酶模拟物，是电压依赖性钙通道阻断剂。它抑制Mpro 和COVID-19病毒，是HIV-1衣壳 CTD 二聚化的抑制剂，具有抗炎、抗癌和抗氧化活性。

P-113 acetate 是一种源自人类唾液蛋白组氨酸 5 的抗菌肽 (AMP)，在患有口腔念珠菌病的牙龈炎和人类免疫缺陷病毒 (HIV) 患者中显示出良好的安全性和有效性。

beta-L-D4A 是一种核苷类型的HIV-1逆转录酶抑制剂。

Helioxanthin 8-1, an analogue of helioxanthin, exhibits significant in vitro anti-HBV/HCV/HSV-1/HIV activity with EC50 of >5/10/1.4/15 μM.

TAK-220 is a selective and orally bioavailable CCR5 antagonist (IC50s: 3.5 nM and 1.4 nM for inhibition on the binding of RANTES and MIP-1α to CCR5, respectively).

(Cholest-5-en-3β-yloxy)acetic acid 作为胆固醇衍生物，主要应用于脂肽复合物的生产。此化合物亦能有效抑制HIV病毒以及其耐药菌株的膜融合过程。

HIV-1inhibitor-80 (compound M44) 是一种功能强大的HIV-1抑制剂，EC50为5-148 nM，在人血浆和人肝微粒体中表现出优良的代谢稳定性和细胞毒性。

R-82913 is a RNA-directed DNA polymerase inhibitor. R 82913 reduce 5-HT2 receptor-mediated DOI-head-shakes in mice. R82913 inhibited the replication of thirteen different strains of HIV-1 in CEM cells with a median IC50 of 0.15 microM. R82913 was 20-fold

ZK 756326 是一种选择性的非肽 CCR8 趋化因子受体激动剂（IC50：1.8 μM，在人体内；2.6 μM，在小鼠体内）。对 CCR4 5 和 CXCR3 4 没有活性，比其他 26 种 GPCR 的选择性高 28 倍（对 α2A 和 5-HT 受体的选择性较低）。诱导趋化性并抑制 Env 介导的 (HIV) 细胞-细胞融合。

β-Rubromycin is a bacterial metabolite originally isolated from Streptomyces that has diverse biological activities.1 It inhibits the growth of HMO2, KATO-III, and MCF-7 cells with GI50 values of 0.5, 0.84, and <0.1 μM, respectively. β-rubromycin inhibits HIV-1 reverse transcriptase activity by 39.7% when used at a concentration of 10 μM. It also has antibacterial activity against Gram-positive bacteria. The structure of β-rubromycin was originally described as containing an ortho-quinone group, but it was revised to a para-quinone group in 2000 using organic and biosynthetic methods, as well as spectroscopic analysis.1,2,3References1. Ueno, T., Takahashi, H., Oda, M., et al. Inhibition of human telomerase by rubromycins: Implication of spiroketal system of the compounds as an active moiety. Biochemistry 39(20), 5995-6002 (2000).2. Puder, C., Loya, S., Hizi, A., et al. Structural and biosynthetic investigations of the rubromycins. Eur. J. Org. Chem. 2000(5), 729-735 (2000).3. Goldman, M.E., Salituro, G.S., Bowen, J.A., et al. Inhibition of human immunodeficiency virus-1 reverse transcriptase activity by rubromycins: Competitive interaction at the template.primer site. Mol. Pharmacol. 38(1), 20-25 (1990). β-Rubromycin is a bacterial metabolite originally isolated from Streptomyces that has diverse biological activities.1 It inhibits the growth of HMO2, KATO-III, and MCF-7 cells with GI50 values of 0.5, 0.84, and <0.1 μM, respectively. β-rubromycin inhibits HIV-1 reverse transcriptase activity by 39.7% when used at a concentration of 10 μM. It also has antibacterial activity against Gram-positive bacteria. The structure of β-rubromycin was originally described as containing an ortho-quinone group, but it was revised to a para-quinone group in 2000 using organic and biosynthetic methods, as well as spectroscopic analysis.1,2,3 References1. Ueno, T., Takahashi, H., Oda, M., et al. Inhibition of human telomerase by rubromycins: Implication of spiroketal system of the compounds as an active moiety. Biochemistry 39(20), 5995-6002 (2000).2. Puder, C., Loya, S., Hizi, A., et al. Structural and biosynthetic investigations of the rubromycins. Eur. J. Org. Chem. 2000(5), 729-735 (2000).3. Goldman, M.E., Salituro, G.S., Bowen, J.A., et al. Inhibition of human immunodeficiency virus-1 reverse transcriptase activity by rubromycins: Competitive interaction at the template.primer site. Mol. Pharmacol. 38(1), 20-25 (1990).

AZT triphosphate TFA (3'-Azido-3'-deoxythymidine-5'-triphosphate TFA) is a active triphosphate metabolite of Zidovudine (AZT). AZT triphosphate TFA exhibits antiretroviral activity and inhibits replication of HIV. AZT triphosphate TFA also inhibits the DNA polymerase of HBV. AZT triphosphate TFA activates the mitochondria-mediated apoptosis pathway[1][2][3]. Treatment with 100 μM Zidovudine (AZT) for 48h disrupts the mitochondrial tubular network via accumulation of AZT triphosphate (AZT-TP) in H9c2 cells. AZT triphosphate accumulation causes downregulation of Opa1 and upregulation of Drp1. AZT triphosphate causes mitochondrial dysfunction, increases the production of cytotoxic reactive oxygen species (ROS), and impairs the balance of the mitochondrial quality control system in H9c2 cell model established from rat embryonic myoblasts[1]. [1]. Ryosuke Nomura, et al. Azidothymidine-triphosphate Impairs Mitochondrial Dynamics by Disrupting the Quality Control System. Redox Biol. 2017 Oct;13:407-417. [2]. Takeya Sato, et al. Engineered Human tmpk/AZT as a Novel Enzyme/Prodrug Axis for Suicide Gene Therapy. Mol Ther. 2007 May;15(5):962-70. [3]. K Y Hostetler, et al. Enhanced Oral Absorption and Antiviral Activity of 1-O-octadecyl-sn-glycero-3-phospho-acyclovir and Related Compounds in Hepatitis B Virus Infection, in Vitro. Biochem Pharmacol. 1997 Jun 15;53(12):1815-22.

Dolutegravir O-β-D-glucuronide is a metabolite of the HIV integrase inhibitor dolutegravir .1It is formed from dolutegravir primarily by the UDP-glucuronosyltransferase (UGT) isoform UGT1A1in vivobut is also metabolized by UGT1A9 in human liver and kidney microsomes and UGT1A3 in human intestinal microsomes.2,1 1.Liu, S.N., Lu, J.B., Watson, C.J.W., et al.Mechanistic assessment of extrahepatic contributions to glucuronidation of integrase strand transfer inhibitorsDrug Metab. Dispos.47(5)535-544(2019) 2.Reese, M.J., Savina, P.M., Generaux, G.T., et al.In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitorDrug Metab. Dispos.41(2)353-361(2013)

Feglymycin is a 13-amino acid peptide originally isolated from Streptomyces that has antibacterial and antiviral activities. It is active against Gram-positive bacteria (MICs = 32-64 μg/ml) and inhibits HIV viral replication in H9 cells (IC50 = ~5 μM). Feglymycin is also active against clinical isolates of HIV-1 from clades A-D, A/E, and G (EC50s = 0.5-6.7 μM). It interacts with gp120 and inhibits HIV-1 NL4.3 binding to human soluble CD4 (EC50 = 4.4 μM) and to CD4+ SupT1 T cells by 74.5% when used at a concentration of 10.5 μM. Feglymycin inhibits the E. coli peptidoglycan biosynthesis enzymes MurA and MurC (Kis = 3.4 and 0.3 μM, respectively) in a noncompetitive manner.

HIV-1 protease-IN-5 是一种 HIV-1 protease 抑制剂 (IC50: 1.64 nM)。HIV-1 protease-IN-5 对野生型和 DRV 耐药型 HIV-1 表现出明显的作用。

KRH-1636 is an orally active, selective and extremely potent CXC chemokine receptor 4 antagonist. KRH-1636 exhibits a potent and selective anti-HIV-1 activity. KRH-1636 efficiently blocked replication of various T cell line-tropic (X4) HIV type 1 (HIV-1) in MT-4 cells and peripheral blood mononuclear cells through the inhibition of viral entry and membrane fusion via the CXC chemokine receptor (CXCR)4 coreceptor but not via CC chemokine receptor 5. KRH-1636 also inhibits binding of the CXC chemokine, stromal cell-derived factor 1alpha, to CXCR4 specifically and subsequent signal transduction. KRH-1636 prevented monoclonal antibodies from binding to CXCR4 without down-modulation of the coreceptor. KRH-1636 seems to be a promising agent for the treatment of HIV-1 infection.

HIV-1integrase inhibitor 10 是一种 HIV-1变构整合酶抑制剂 (ALLINI)，具有口服活性。HIV-1integrase inhibitor 10 可抑制 NLRepRluc 病毒在 MT-2 细胞中的生长，其 EC50值为 3-5 nM。HIV-1integrase inhibitor 10 可用于人类免疫缺陷病毒-1 (HIV-1) 的研究。

Reverse transcriptase-IN-3, 作为一种嘧啶-5-羧酰胺衍生物，主要用于抑制HIV-1。它对HIV-1野生型及其突变型病毒株均展示出高效的抑制活性。

α-Lipoic Acid (Thioctic acid) sodium 是一种抗氧化剂，是线粒体酶复合物的重要辅助因子。α-Lipoic Acid sodium 可抑制NF-κB 依赖性的HIV-1LTR 活化。α-Lipoic Acid sodium 诱导内质网应激 (ERS) 介导的肝癌细胞凋亡 (apoptosis)。α-Lipoic Acid sodium 可与CPUL1 合成自组装的纳米聚合体 CPUL1-LA NA，其抗肿瘤效果优于 CPUL1。

HIV-1protease-IN-4 (Compound II-22) 是一种有效的HIV-1蛋白酶抑制剂。HIV-1protease-IN-4 是阿扎那韦的前体。HIV-1蛋白酶-IN-4 作为前体，与口服母体活性分子相比，将母体 1 输送到大鼠血浆中的 AUC 高 5 倍，C24 高 67 倍[1]。

NSC260594是一种化合物，具有诱导细胞凋亡（Apoptosis）的作用。它通过与Mcl-1蛋白的浅沟结合并下调Wnt信号蛋白，抑制Mcl-1的表达。此外，NSC260594能够识别HIV的G9-G10-A11-G12 RNA四环，防止5'-UTR中的Gag蛋白结合。它被认为对抑制肿瘤生长具有潜在作用，特别是在三阴性乳腺癌（TNBC）研究中。